Doug Hirsch, Co-Founder and C0-CEO of GoodRx.
Heidi Petty | CNBC
GoodRx, an organization that helps shoppers entry pharmaceuticals at a reduction, filed to go public on Friday. The corporate will checklist on the Nasdaq underneath the image GDRX.
However GoodRx has one factor these different fast-growing corporations don’t: A document of constant profitability.
According to the filing, the corporate earned $55 million in revenue for first half of 2020, up from $31 million within the first half of 2019 — a soar of 75%. Revenues for the primary half of 2020 have been $257 million, up from $173 million within the first half of 2019, for progress of 48%.
In 2019, it pulled in $66 million in revenue on $388 million in income. The submitting reveals earnings all the way in which again to 2016, the earliest yr for which monetary info is included, and the corporate previously told CNBC that it has been worthwhile on-and-off since 2013.
GoodRx’s profitability is a rarity amongst start-ups submitting to go public. One other notable example is Zoom, the under-the-radar videoconferencing software program that made its debut in April of 2019. That firm’s inventory is up greater than eightfold since its debut and has gained 339% this yr, as the worldwide coronavirus pandemic saved folks dwelling and spurred demand for brand new methods to speak remotely.
GoodRx, which relies in Southern California, was founded in 2011 by Fb veteran Doug Hirsch and serial software program entrepreneur Trevor Bezdek. The corporate noticed a necessity to enhance transparency within the extremely complicated world of pharmaceuticals. So it constructed a set of low cost playing cards and coupons for shoppers to take to the pharmacy, usually permitting them to get a lower cost.
It makes its cash by accumulating charges from the pharmacy advantages managers, or PBMs, that it really works with at any time when shoppers current their GoodRx coupon on the pharmacy. About 17 million folks use GoodRx each month. Going ahead, it plans to increase into new areas, together with telemedicine.
Nevertheless, the enterprise may take successful if policymakers transfer to upend the drug provide chain. If shoppers have been lined by insurance coverage and drug costs have been extra clear and reasonably priced, there could be much less of a necessity for GoodRx.
Hirsch has previously said: “If America as a rustic determined to maintain all People wholesome and issues have been upfront and clear, there could be no want for GoodRx. I do not suspect that’ll occur, but when it did, I might fortunately hold up my hat and transfer on to a different downside.”
The IPO is being led by Morgan Stanley, Goldman Sachs and JP Morgan. The corporate has beforehand raised financing from non-public fairness corporations specializing in expertise and well being, together with Silver Lake and Francisco Companions. It was valued around $2.8 billion in a 2018 financing spherical.
GoodRx was no. 20 on this yr’s CNBC Disruptor 50 checklist of promising non-public corporations.